Table 4. In Vitro/In Vivo Profile of Compound 27^a.

27: MW = 557, TPSA = 112, log D7.4 = 3.8
human LM Clint/Hep Clint	7.2/41
rat LM Clint/Hep Clint	43/33
dog LM Clint/Hep Clint	20/21
cyno LM Clint/Hep Clint	55/80
cyno IV PK Cl (mL min–1 kg–1)b (Clu)c	31.8 (611)
cyno IV PK t1/2 (h)	2.9

^aLM Cl_int represents intrinsic clearance obtained from isolated microsomes (units = μL/min/mg) with NADPH, and Hep Cl_int represents intrinsic clearance obtained from isolated hepatocyte cells (units = μL/min/million cells).

^bCynomolgus monkey, 0.5 mg/kg IV and 5 mg/kg PO dose. For IV and PO dosing, 27 was formulated in 5% DMSO + 5% kolliphor HS 15 + 90% saline vehicle. Cl: plasma clearance after administration of single IV bolus dose.

^cCl_u: unbound in vivo clearance (in vivo cyno clearance/free fraction in cyno), free fraction calculated from plasma protein binding determined by ultracentrifugation method.